

25 pages
5112 words
29 references
0 tables
5 figures

Stabilized NADH as a Countermeasure for Jet Lag

Gary G. Kay, Ph.D.
Erik Viirre M.D., Ph.D.
Jonathan Clark, M.D.

Running Head:

Stabilized NADH and Jet Lag

Please send Correspondence to:

Gary G. Kay, Ph.D.
Director
Washington Neuropsychological Institute
4910 Massachusetts Ave., NW Suite 100
Washington, DC 20016
(202) 686 7520

Abstract

Background: Current remedies for jet lag (phototherapy, melatonin, stimulant, and sedative medications) are limited in efficacy and practicality. The efficacy of a stabilized, sublingual form of reduced nicotinamide adenine dinucleotide (NADH, ENADAlert[®], Menuco Corp.) as a countermeasure for jet lag was examined.

Hypothesis: Because NADH increases cellular production of ATP and facilitates dopamine synthesis, it may counteract the effects of jet lag on cognitive functioning and sleepiness. **Methods:** Thirty-five healthy, employed subjects participated in this double-blind, placebo-controlled study. Training and baseline testing were conducted on the West Coast before subjects flew overnight to the East Coast, where they would experience a 3-hour time difference. Upon arrival, individuals were randomly assigned to receive either 20 mg of sublingual stabilized NADH (n=18) or identical placebo tablets (n=17). All participants completed computer-administered tests (including CogScreen7) to assess changes in cognitive functioning, mood, and sleepiness in the morning and afternoon. **Results:** Jet lag resulted in increased sleepiness for over half the participants and deterioration of cognitive functioning for approximately one third. The morning following the flight, subjects experienced lapses of attention in addition to disruptions in working memory, divided attention, and visual perceptual speed. Individuals who received NADH performed significantly better on 5 of 8 cognitive and psychomotor test measures ($P < .05$) and showed a trend for better performance on the other three measures ($P \leq .10$). Subjects also reported less sleepiness compared with those who received placebo. No adverse effects were observed with NADH treatment. **Conclusions:** Stabilized NADH significantly reduced jet lag-induced disruptions of cognitive functioning, was easily administered, and was found to have no adverse side effects.

Keywords: jet lag, cognitive testing, fatigue countermeasures, NADH

Jet lag is a constellation of symptoms that occur after flying across time zones. It affects a large number of travelers and aircrew (1). These symptoms include: general malaise and fatigue, disrupted sleep, gastrointestinal distress, and memory loss (2-7). Rosekind (8) estimates that jet lag can degrade decision-making abilities, communication, and memory by 30% to 70%. The disruption of the body's entrainment of internal 24-hour cycles of temperature, sleep initiation and other activities to the day-light cycle is believed to be the trigger for jet lag (9, 10). Today's modern jet traveler (soldier, businessperson, athlete, or tourist) often is required to perform at a high functional level upon reaching their destination. Furthermore, the problems of jet lag have been compounded in recent years because business travelers are taking more international trips and staying fewer days at their destination.

Research on the mitigation of jet lag has emphasized methods to speed the entrainment of the circadian rhythm to the new time zone (11). These methods include sleep scheduling, phototherapy, and administration of sedative and/or stimulant medications (12-14). Each of these methods has been found to have some merit, though each has potential adverse side effects and some are considered impractical (15).

An alternative approach to countering the effects of jet lag is to provide the traveler with the additional energy and alertness needed to mitigate jet lag symptoms while readjusting to a new time zone. One potential method for providing energy is the energy producing coenzyme NADH (β -nicotinamide adenine dinucleotide, reduced form Coenzyme 1). We investigated the effects of stabilized, sublingual NADH on the cognitive functioning of healthy individuals on the day following an overnight flight across North America. The sublingual form of NADH (ENADAlert™, Menuco

Corporation) was chosen to maximize the absorption and optimize bioavailability of the coenzyme. Previously, NADH has been shown to facilitate production of dopamine and norepinephrine (16). Furthermore, NADH has been demonstrated to increase cellular energy production of ATP (17), to aid in the repair of damaged DNA (18), and to function as a potent antioxidant (19). All of these properties of NADH led us to investigate the compound as a potential countermeasure for jet lag. Furthermore, clinical studies have demonstrated that oral NADH is effective in reducing symptoms of chronic fatigue syndrome, Parkinson's disease, Alzheimer's disease, and depression (20-23). In these studies, long-term (4-week to 6-month) oral use of stabilized NADH was associated with clinical improvement in energy level and cognitive functioning without adverse effects.

We hypothesized that administration of sublingual NADH to travelers would specifically result in a reduction of the impact jet lag has on cognitive functioning and sleepiness, enabling travelers to return to their normal levels of physical and mental activity upon arriving in a new time zone.

METHODS

Subjects

Subjects (n=36) were volunteers between 35 and 55 years of age, in good general physical health. All subjects were verbally informed of the intent and procedures of the study during a pre-screening telephone interview. Written informed consent was obtained prior to the history and physical. At the screening visit, subjects were urine tested to screen for the use of illicit drugs and pregnancy. Cognitive screening with the Trail Making Test and Symbol Digit Modalities Test (24) was used to exclude subjects

with cognitive function test scores > 1 SD below the mean for their age. Subjects were required to be gainfully employed, to have completed 14 years of formal education, and to have none of the following conditions; history of substance abuse, obesity (body mass index $> 30 \text{ kg/m}^2$), air sickness, pregnancy, nicotine use (within 6-months), mental health disorder (within 1 year), or sleep disorder. In addition, subjects were required to have a normal day/night sleep schedule in their home time zone, and to have an Epworth Sleepiness Scale rating > 8 at baseline (25). Subjects were not permitted to be taking antidepressant medications, CNS stimulants, neuroleptics, Ginseng, Gingko Biloba, melatonin, phosphatylcholine, n-acetyl carnatene, or other medications/nutritional supplements reported to enhance cognitive functioning within 90 days of the study. During the study, subjects were not permitted to use caffeine, alcohol or to take any prescription or over-the-counter medications known to enhance or depress CNS functioning. The study protocol and consent form were reviewed and approved for human subjects by the Biomedical Research Institute of America (San Diego, California).

Procedure

Subjects arrived at the San Diego, California test site at 1200 hours on the day of the flight. The study protocol was reviewed with the subjects and they were then each issued a laptop computer (IBM Thinkpad Model 760) and familiarized with the tests and measures to be used in the study. At approximately 1500 hours subjects were administered the entire battery of tests to establish their baseline performance (Baseline). Subjects also received training in the method for taking the sublingual tablets. Subjects were transported to the San Diego Airport and flown to Phoenix, Arizona where they were shuttled to a conference room at a nearby hotel, provided dinner, and readministered the battery of tests at approximately 2030 hours. Subjects were shuttled back to the airport and boarded a flight to Baltimore, Maryland at 2230 hours. Thirty minutes into the flight the subjects were instructed to complete a subset of the battery of tests.

Subjects were permitted to sleep after completing the tests. The duration of the flight from Phoenix to Baltimore is approximately 4 hours. Furthermore, there is a 3-hour time difference between San Diego and Baltimore. The local time in Baltimore upon arrival was approximately 0600 hours. After breakfast, subjects were shuttled to the Washington, DC test site where they arrived at approximately 0800 hours.

Sublingual NADH 20 mg (4 tablets of sublingual ENADAlert® 5 mg) or an equal number of identical placebo tablets were administered by study site personnel to the subjects upon their arrival at the Washington test site. At the test site, subjects' activities were carefully monitored to avoid dehydration, exposure to daylight (subjects were kept indoors) and hunger (they were provided breakfast and lunch, which all subjects ate.) Caffeine intake was strictly prohibited. Study drug was provided in moisture-proof, airtight, labeled medication bottles labeled with the subject's identification number.

Subjects completed the battery of tests 90 minutes after dosing, at approximately 0930 hours (AM test). Testing was repeated at 1230 hours (PM test). Subjects were dismissed from the study at 1400 hours.

Measurements

Cognitive Tests

Kay Continuous Performance Test (KCPT) (26)

This test provides a measure of sustained attention and vigilance. On this computer-administered cognitive test, subjects watch a computer monitor and respond only when seeing a target symbol that occurs at low frequency (i.e., 5%). The number of errors of omission (i.e., lapses of attention) and errors of commission were used to calculate total errors.

CogScreen

The following four CogScreen subtests were administered:

Shifting Attention Test: Instruction Condition: Measure of working memory.

Subject reads a two-word instruction and then applies the instruction to the screen that follows. The accuracy, throughput (number of correct responses per minute), and median response time for correct responses were recorded.

Matching to Sample Test: Measure of visual perceptual processing speed and working memory: Subject views a 4x4 checkerboard pattern and then on the screen that follows, the subject selects the matching checkerboard pattern. The accuracy of responses, the throughput (number of correct responses per minute) and the median response time for correct responses were recorded.

Visual Sequence Comparison: Measure of visual processing of number/letter sequences: The accuracy of responses, the throughput (number of correct responses per minute) and the median response time for correct responses (VSCRTC) were recorded.

Dual Task Test: Tracking Alone: Measure of psychomotor functioning.

Subject's task is to maintain the central position of an unstable cursor that moves along a horizontal line using the left and right cursor keys. The average absolute tracking error and the number of tracking failures were recorded.

Mark Numbers Test: Complex Cognitive Assessment Battery (CCAB) (27)

Computer-administered test measuring working memory and divided attention:

The subject identifies and "marks" numbers in a spreadsheet according to an instruction

(e.g. Mark all even numbers between 20 and 46). While performing this task, the subject is interrupted and instructed to locate and mark the smaller or larger of two flashing numbers. After performing the secondary task the subject resumes the primary task. The total score (a derived measure of the total number of correct marks, the speed of completing the task, and performance on the secondary task, and the mean reaction time to responding to the secondary task were recorded.

Automated Neuropsychological Assessment Metrics (ANAM) (26)

Two sub-tests were selected from the ANAM battery of tests:

Running Memory Test: Measure of vigilance and working memory: Subject is instructed to indicate whether or not the letter being shown on the screen is the same as the previous letter. The accuracy of responses, the throughput (number of correct responses per minute) and the mean response time for correct responses were recorded.

Math Test: Measure of working memory and math reasoning: Subject is presented with 3 numbers and two operation signs (e.g., $3 + 5 - 2$) and is instructed to decide whether the total is greater than 5 or less than 5. The accuracy of responses, the throughput (number of correct responses per minute) and the mean response time for correct responses were recorded.

Self-Report Mood Measures

Walter Reed Mood Scale (26)

Subjects indicate their agreement or disagreement with an adjective that is presented as a description of their current mood. Scales include measures of fatigue and activity.

Stanford Sleepiness Scale (25)

This is a 7-point self-report scale of current sleepiness, with 1 being least sleepy and 7 being most sleepy.

Statistical Analyses

For continuous measures, the effects of sublingual NADH were assessed by repeated measures analysis of variance (SPSS-PC, Version 10.7). Tests with categorical results (KCPT errors of omission and commission, Dual Task Test Hits, Stanford Sleepiness Scale) were analyzed by Chi-square test. These methods were used to provide a comparison of the NADH and placebo groups at Baseline in San Diego, CA, the morning in Washington, D.C. (AM), and the afternoon in Washington, D.C. (PM). Significant group by session interaction effects are reported. Statistical significance was set at $P < .05$.

RESULTS

Subject Demographics: Thirty-six subjects enrolled in the study (19 males and 17 females) between 35 and 55 years of age. One male subject who had completed screening failed to appear for the test session. Subjects were randomly assigned to the placebo and NADH groups. The groups did not differ in age (NADH age = 43.9 \pm 6.9; Placebo 42.8 \pm 6.1) or gender composition (NADH 9 males/9 females; Placebo 9 males/8 females).

Adverse Events: Fourteen subjects reported having headaches during the study. The onset of the headache occurred before the administration of NADH or placebo for ten of these subjects. Two subjects in each group had headaches that began after the administration of either NADH or placebo. Subjects were given acetaminophen or

ibuprofen for the headaches. For eight subjects the headache resolved prior to the administration of NADH or placebo.

Vigilance: The ANAM Running Memory Test and the KCPT were the primary measures of vigilance. Useable data for the ANAM Running Memory Test was obtained for only 28 subjects. Five of the subjects were not using the correct key to respond and two subjects had response times (at all 3 sessions) that were extreme outliers. For the remaining 14 NADH and 14 placebo subjects, there was a baseline difference in reaction time ($P = .005$). However, the groups did not differ at baseline with respect to number of items completed or accuracy. The Group x Session interaction is significant for accuracy ($P = .036$). Accuracy for placebo subjects dropped from 95% at baseline to 91% at the AM and PM testing. For NADH subjects Running Memory accuracy scores remained stable across all three sessions at approximately 96% [Figure 1 Here].

On the KCPT test, there were no group differences at baseline. Only data for the 30 subjects with a normal baseline performance (i.e., 0 to 1 omission error) were analyzed. Twelve of the 30 subjects (36% NADH, 44% Placebo) made two or more errors in the AM. *By the PM, subjects receiving NADH made significantly fewer total errors (compared to baseline) than subjects receiving placebo ($p < .05$). Eighty six percent of NADH subjects had resumed a normal level of performance compared to 63% of placebo subjects ($P < .08$).*

Working Memory: There were no baseline group differences on the Shifting Attention Test-Instruction Condition. The Group x Session effect was significant ($P < .05$). Analysis of contrasts shows that subjects in the NADH group correctly completed 13.2 more problems per minute at AM vs. baseline compared to 6.8 more problems correctly completed per minute for the placebo group. For the placebo subjects, accuracy dropped from 93% at baseline to 91% at the AM test. For NADH subjects performance improved from 92.5% at baseline to 95% at the AM test session [Figure 2 Here].

On the ANAM Math Test the Group x Session effect approached significance for the measure of throughput ($P < .07$). For subjects in the NADH group there was a 15%

improvement relative to baseline at the AM test and an 11% improvement at the PM test. By comparison, subjects in the placebo group showed a 6% improvement at the AM test and a 4% improvement at the PM Test. The mean difference between groups was not significant ($P < .08$).

Divided Attention: The primary measure of divided attention was the secondary task reaction time and total score for the CCAB Mark Numbers Test. The Group x Session effect was significant for the secondary task reaction time ($P = .038$) and for the Total Score ($P = .032$). The secondary task reaction time decreased for NADH subjects by 0.15 seconds and increased by 0.44 seconds for the placebo subjects ($P = .016$). The PM Total score for NADH subjects increased by 77.5 points, compared to an increase of 19.2 points for placebo subjects ($P = .011$) [Figure 3 Here].

Visual Perceptual Speed and Accuracy: The CogScreen Matching to Sample and Visual Sequence Comparison tests provided measures of visual perceptual speed and accuracy. For the Visual Sequence Comparison Test there was a significant Group x Session interaction for the throughput measure (correct responses per minute; $P = .05$). NADH subjects correctly completed 5.4 more items per minute at the PM test compared to baseline. By comparison, the placebo subjects correctly completed 1.4 more items per minute ($P = .026$). There was no significant Group x Session effect for the Matching to Sample Test. Nevertheless, the NADH group showed a tendency ($P = .078$) for more improvement in throughput from baseline to PM testing; 4.9 more correct responses per minute compared to 1.0 more correct response per minute for placebo subjects [Figure 4 Here].

Psychomotor Performance: The CogScreen Dual Task Test Tracking Alone measure provides a measure of skilled motor activity. This critical instability tracking

test measures the number of tracking failures during a 90 second trial. There is generally an improvement (i.e., a practice effect) on this test reflected by fewer subjects making tracking errors over trials. This pattern of performance is evident for the NADH group where 31% had tracking failures at baseline, 33% at the AM test and 11% at the PM test. In contrast, for the subjects in the placebo group, 29% had tracking failures at baseline, 41% at the AM test and 29% at the PM test. Group comparisons show a trend for better tracking performance for NADH subjects ($P<.09$).

Sleepiness and Mood: At baseline, 14 subjects (82%) in the NADH group rated their sleepiness a 1 or 2 on the 7-point Stanford Sleepiness Scale (SSS) and three subjects rated their sleepiness a 3. Sixteen placebo subjects (94%) rated their sleepiness a 1 or 2 at baseline. One placebo subject had a sleepiness rating of 3. One NADH subject was an extreme outlier on the SSS and was excluded from the SSS analyses. In the morning, both groups had identical sleepiness ratings; six in each group (35%) had a rating of 1 or 2 and 11 (65%) had ratings of 3 or more. However, in the afternoon there was a trend toward less sleepiness in the NADH group ($p=.07$); eight had ratings of 1 or 2 and nine had ratings of 3 or more. For the placebo group, four subjects had ratings of 1 or 2 and 13 had ratings of 3 or more [Figure 5 Here]. There were no significant differences found between groups on measures of self-reported fatigue and activity level.

DISCUSSION

The study was designed to transport subjects across time zones, in a controlled environment, so that we could assess the impact of jet lag as well as the effects of a potential jet lag countermeasure. Results indicated that an overnight ("red-eye") flight across four time zones was effective in generating subjective symptoms of jet lag including fatigue and sleepiness. The cognitive test employed in the study (CogScreen) detected cognitive changes following the flight. Furthermore, stabilized NADH was

found to have a beneficial effect on cognitive functioning and sleepiness when administered upon arrival. NADH appears to mitigate the effects of jet lag on cognitive and psychomotor functions considered particularly sensitive to sedation; vigilance, working memory, visuomotor tracking and divided attention. In addition, NADH showed a trend to reduce the number of subjects experiencing self-reported sleepiness.

Though there were 14 subjects that reported headaches during the study, only 2 occurred after the administration of NADH. Because only 2 occurred after the supplement, we deemed that there were no adverse effects attributable to it. The absence of problems corresponds to the findings in the administration of NADH in other clinical studies (20, 22, 23).

On measures of vigilance there was a notable increase in lapses of attention, as reflected by omission errors on the two continuous performance tests (KCPT and ANAM Running Memory Test). These lapses of attention were most evident in the morning following the flight. By the afternoon, only 14% of NADH subjects had omission errors on the KCPT and mean accuracy on the Running Memory Test was 96%. In contrast, 37% of placebo subjects made omission errors on the KCPT and the mean accuracy on the Running Memory Test was 91%.

NADH also appears to have a protective effect on working memory, the ability to temporarily hold information in mind and to perform a mental operation on the information. On the morning test, subjects who received NADH showed an improvement in accuracy on the Shifting Attention Test - Instruction Condition. In sharp contrast, accuracy dropped for subjects in the placebo condition. On a second measure of working memory, ANAM Math Test, there was also a trend for better performance.

Jet lag clearly has a negatively impact on divided attention, the ability to perform simultaneous mental operations. During the morning test session, subjects who received placebo were 0.15 seconds slower, compared to baseline, in their response to the secondary task on the CCAB Mark Numbers Test. By comparison, subjects who

received NADH improved, compared to baseline, by 0.44 seconds on this task.

Furthermore, the total score on the Mark Numbers test improved significantly more for subjects who received NADH.

On two measures of visual perceptual speed and accuracy (CogScreen Visual Sequence Comparison and Matching to Sample), NADH subjects demonstrated greater improvement in the number of correct responses per minute at the afternoon test session, compared to the placebo subjects.

The impact of the jet lag protocol on sleepiness is evident in the ratings provided by subjects on the Stanford Sleepiness Scale. During the morning test session 57.1% of the subjects in the NADH group and 62.5% of the subjects in the placebo group reported an increase in sleepiness compared to baseline. By the afternoon test session, 57.7% of the NADH subjects were no longer reporting an increase in sleepiness relative to their baseline rating. By comparison, only 25% of the placebo subjects were no longer reporting increased sleepiness.

We have subsequently had an opportunity to test an additional 11 subjects following the same protocol. With the addition of these subjects ($n=46$), the effect on sleepiness, as measured by the Stanford Sleepiness Scale, reached significance ($P<.02$). At the afternoon test 48% of NADH subjects reported no sleepiness, compared to 18% of placebo subjects.

The public health, occupational health, and economic impact of jet lag have likely been underestimated (28). There are an increasing number of business travelers making transcontinental and intercontinental flights. These travelers are subjected to the effects of jet lag demonstrated in the current study. The "jet lagged traveler" is more likely to experience lapses of attention (i.e., vigilance errors), to have difficulty concentrating (i.e., working memory difficulty), and to be less efficient at handling the demands of the work environment (i.e., decreased divided attention). In addition the jet lagged traveler feels less alert, less active and more fatigued. For the traveling athlete these effects of jet lag

are likely to be evident in reduced performance. Travelers, and the aircrew who transport them, need to be made more aware of the effects and consequences of jet lag. They also need to learn about the benefits and risks of different jet lag countermeasures(11).

Employers, business travelers, and athletes need to adjust their expectations and allow for an adequate opportunity to recover from the effects of jet lag.

The implications of this work are that activities such as executive decision making or athletic performance that require attention to multiple tasks, continuous concentration and rapid interpretation of visual cues will be affected by travel across time zones.

Stabilized NADH was effective in mitigating against these cognitive effects. Piloting an aircraft is critically dependent on vigilance, memory and visual perception. Solutions for jet lag that involve attempts to realign circadian rhythms appear to be especially impractical for commercial pilots (29). In contrast, NADH may prove to be especially useful as a jet lag or fatigue countermeasure for aircrew.

Sublingual stabilized NADH appears to be a suitable short-term countermeasure for the effects of jet lag on cognition and sleepiness. In the current study, subjects receiving NADH showed less reduction of cognitive functioning and were more likely to be functioning at their baseline (pre-flight) level than subjects who received placebo. Further studies are needed to replicate and extend the present findings. In particular, there is a need to investigate optimal dosing parameters for this use of NADH. What is the duration of the effect of NADH on cognition and self-reported sleepiness? Furthermore, there is a dearth of evidence on the duration and course of the cognitive performance decrements over time that result from jet lag. Would NADH be helpful for symptoms occurring 48 to 72 hours after travel? Other conditions where sleep schedules and circadian rhythms are disturbed such as night call and shift work should also be investigated.

ACKNOWLEDGMENTS

Menuco Corporation (New York) funded the study. The authors thank Robert Sitarz, Melissa Longstreet, Victoria Starbuck, Ph.D., Mildred Medina, and Linda Swope for their assistance in monitoring subjects during the testing procedures.

REFERENCES

1. Winget CM, DeRoshia CW, Markley CL, Holley DC. A review of human physiological and performance changes associated with desynchronization of biological rhythms. *Aviat Space Environ Med* 1984;55(12):1085-96.
2. Spitzer RL, Terman M, Williams JB, Terman JS, Malt UF, Singer F, et al. Jet lag: clinical features, validation of a new syndrome-specific scale, and lack of response to melatonin in a randomized, double-blind trial. *Am J Psychiatry* 1999;156(9):1392-6.
3. Youngstedt SD, O'Connor PJ. The influence of air travel on athletic performance. *Sports Med* 1999;28(3):197-207.
4. Waterhouse J, Reilly T, Atkinson G. Jet-lag [see comments]. *Lancet* 1997;350(9091):1611-6.
5. Sasaki M, Kurosaki Y, Mori A, Endo S. Patterns of sleep-wakefulness before and after transmeridian flight in commercial airline pilots. *Aviat Space Environ Med* 1986;57(12 Pt 2):B29-42.
6. Samel A, Wegmann HM, Vejvoda M. Jet lag and sleepiness in aircrew. *J Sleep Res* 1995;4(S2):30-36.
7. Cho K, Ennaceur A, Cole JC, Suh CK. Chronic jet lag produces cognitive deficits. *J Neurosci (Online)* 2000;20(6):RC66.
8. Rosekind MR, Gander PH, Miller DL, Gregory KB, Smith RM, Weldon KJ, et al. Fatigue in operational settings: examples from the aviation environment. *Hum Factors* 1994;36(2):327-38.
9. Copinschi G, Spiegel K, Leproult R, Van Cauter E. Pathophysiology of human circadian rhythms. *Novartis Found Symp* 2000;227:143-57.

10. Turek FW, Losee-Olson S. Entrainment of the circadian activity rhythm to the light-dark cycle can be altered by a short-acting benzodiazepine, triazolam. *J Biol Rhythms* 1987;2(4):249-260.
11. Stone BM, Turner C. Promoting sleep in shiftworkers and intercontinental travelers. *Chronobiol Int* 1997;14(2):133-43.
12. Koelega HS. Stimulant drugs and vigilance performance: a review. *Psychopharmacology* 1993;111(1):1-16.
13. Petrie K, Dawson AG, Thompson L, Brook R. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. *Biol Psychiatry* 1993;33(7):526-30.
14. Wever RA. Use of light to treat jet lag: differential effects of normal and bright artificial light on human circadian rhythms. *Ann N Y Acad Sci* 1985;453:282-304.
15. Caldwell JA, Jr. Fatigue in the aviation environment: an overview of the causes and effects as well as recommended countermeasures. *Aviat Space Environ Med* 1997;68(10):932-8.
16. Pearl SM, Antion MD, Stanwood GD, Jaumotte JD, Kapatos G, Zigmond MJ. Effects of NADH on dopamine release in rat striatum. *Synapse* 2000;36(2):95-101.
17. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Energy Conversion: Mitochondria and chloroplasts. In: *Molecular biology of the cell*. 3rd ed. New York: Garland; 1994.
18. Zhang JR, Vrecko K, Nadlinger K, Storga-Tomic D, Birkmayer GD, Reibnegger G. The reduced coenzyme nicotinamide dinucleotide (NADH) repairs DNA damage of PC12 cells induced by doxorublein. *J Tumor Marker Oncol* 1998;13:5-17.
19. Stryer L. Oxidative Phosphorylation. In: Stryer L, editor. *Biochemistry*. 3rd ed. San Francisco and New York: W.H. Freeman and Co.; 1988.
20. Forsyth LM, Preuss HG, MacDowell AL, Chiazze L, Jr., Birkmayer GD, Bellanti JA. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. *Ann Allergy Asthma Immunol* 1999;82(2):185-191.

21. Birkmayer W, Birkmayer GJ, Vrecko K, Mlekusch W, Paletta B, Ott E. The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients. *J Neural Transm Park Dis Dement Sect* 1989;1(4):297-302.
22. Birkmayer JG, Vrecko C, Volc D, Birkmayer W. Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. *Acta Neurol Scand Suppl* 1993;146:32-35.
23. Birkmayer JG. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. *Ann Clin Lab Sci* 1996;26(1):1-9.
24. Lezak MD. *Neuropsychological assessment*. 3rd ed. New York: Oxford University Press; 1995.
25. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. *Psychophysiology* 1973;10(4):431-6.
26. Kane RL, Kay GG. Computerized assessment in neuropsychology: a review of tests and test batteries. *Neuropsychol Rev* 1992;3(1):1-117.
27. Samet M ea. *Complex Cognitive Assessment Battery (CCAB): Test Descriptions*. Alexandria, VA: US Army Research Institute; 1986.
28. Mitler MM, Carskadon MA, Czeisler CA, Dement WC, Dinges DF, Graeber RC. Catastrophes, sleep, and public policy: consensus report. *Sleep* 1988;11(1):100-9.
29. Samel A, Wegmann HM, Vejvoda M. Aircrew fatigue in long-haul operations. *Accid Anal Prev* 1997;29(4):439-52.

Legends for Illustrations

Figure 1: Mean accuracy by group on the ANAM Running Memory Test, across the 3 test sessions. Results show a significant group by session interaction ($P=.036$).

Note: Baseline refers to the testing in San Diego on the day of the flight; AM refers to morning testing in Washington, DC; PM refers to afternoon testing in Washington, DC.

Figure 2: Mean accuracy by group on the Shifting Attention Test Instruction Condition, across the 3 test sessions. Results show a significant group by session effect ($P<.05$).

Figure 3: Reaction time on the secondary task of the Complex Cognitive Assessment Battery Mark Numbers Test, across the 3 test sessions. Results show a significant group by session effect ($P=.038$).

Figure 4: Correct responses per minute (throughput) on the Visual Sequence Comparison test, across the 3 test sessions. Results show a significant group by session interaction ($P=.05$).

Figure 5: Subjects reporting sleepiness on the Stanford Sleepiness Scale (rating > 2). Results show a trend for less sleepiness in the NADH group in the PM ($P=.07$).




Figure 1




Figure 2




Figure 3

VISUAL PERCEPTUAL SPEED & ACCURACY

Visual Sequence Comparison: Thruput




Figure 4




Figure 5